Anti-platelet derived growth factor (anti-PDGF) therapy resulted in enhanced visual outcome and was associated with significant neovascular regression.
Approximately 59% of patients treated with anti-PDGF and anti-vascular endothelial growth factor (anti-VEGF) gained significant vision (three-line gain) at week 12 after therapy. Approximately 100% of treated patients demonstrated neovascular regression. E10030 was well tolerated with no evidence of drug-related adverse events.
Current standard of care treatment utilizing monotherapy anti-VEGF results in three-line visual gain in approximately one third of patients and without significant neovascular regression.
Samir Patel, president and CEO of Ophthotech, said: “It is exciting to see our clinical trial confirm the strong preclinical data from oncology and ophthalmic studies targeting the molecules regulating pericyte and endothelial cell survival. Ophthotech will continue to devote its resources towards an accelerated development of our anti-PDGF compound.”